{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:52:31Z","timestamp":1778136751535,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Decreased baroreflex sensitivity (BRS) has been shown to be a marker of cardiovascular (CV) risk. In the present study, the difference in CV risk biomarkers in type 2 diabetes (T2D) patients receiving oral antidiabetic drugs (OAD) with and without hypertension has been assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Ninety-two T2D patients on OAD without hypertension (control group) and eighty-eight diabetic patients with hypertension on OAD and antihypertensive drugs (test group) matched for age, gender, body mass index, serum glucose, glycated haemoglobin, and duration of the disease were recruited for the study. Their blood pressure (BP) variability including BRS, heart rate variability (HRV), insulin, lipid profile, osteoprotegerin (OPG), and tumor necrosis factor-\u03b1 (TNF-\u03b1) were estimated. The association of various factors with BRS was assessed by Spearman correlation and multiple regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>BRS was decreased (13.90\u2009\u00b1\u20095.27 vs 6.76\u2009\u00b1\u20094.58), HRV sympathetic indices [LFnu, LF-HF ratio (1.30\u2009\u00b1\u20090.49 vs 1.93\u2009\u00b1\u20090.62)], HOMA-IR, atherogenic index of plasma (AIP), OPG (223.08\u2009\u00b1\u2009103.86 vs 287.60\u2009\u00b1\u2009121.36) and TNF-\u03b1 were increased, and parasympathetic indices [TP (1012.90\u2009\u00b1\u2009316.18 vs 625.88\u2009\u00b1\u2009229.84), RMSSD, SDNN, NN50, pNN50] were decreased in the test group compared to control group. In control group, parasympathetic indices, AIP, OPG, and TNF-\u03b1 had a significant correlation and OPG had an independent association (\u03b2 \u2212\u20090.344; p 0.004) with BRS. In test group, BP, LF-HF ratio, parasympathetic indices, AIP, OPG, and TNF-\u03b1 had significant correlation, and TNF-\u03b1 alone (\u03b2 \u2212\u20090.297; p 0.022) had an independent contribution to decreased BRS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite antidiabetic and antihypertensive treatments, T2D patients with hypertension had more cardiometabolic risks in comparison to normotensive T2D patients. Inflammation could be the inciting factor for rise in BP and decrease in BRS (CV risk) in hypertensive T2D patients. Hypertension in diabetes could attenuate the link of OPG to the reduction in BRS. Reduction in BRS could be a physiological marker of CV risk in T2D patients treated with OAD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01137-w","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T15:12:49Z","timestamp":1662736369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hypertension attenuates the link of osteoprotegerin to reduced baroreflex sensitivity in type 2 diabetes mellitus patients on oral antidiabetic and antihypertensive therapy \u2013 a cross sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"A. Naga","family":"Sailaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nivedita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. S.","family":"Suryanarayana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"1137_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1161\/HYPERTENSIONAHA.111.00612","volume":"61","author":"JR Sowers","year":"2013","unstructured":"Sowers JR. Diabetes and vascular disease. Hypertension. 2013;61:943\u20137.","journal-title":"Hypertension"},{"key":"1137_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ecl.2013.09.005","volume":"43","author":"G Lastra","year":"2014","unstructured":"Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin N Am. 2014;43:103\u201322.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"1137_CR3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1093\/eurheartj\/ehm501","volume":"28","author":"G Hu","year":"2007","unstructured":"Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J. 2007;28:3059\u201366.","journal-title":"Eur Heart J"},{"key":"1137_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2337\/dci17-0026","volume":"40","author":"IH de Boer","year":"2017","unstructured":"de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:1273\u201384.","journal-title":"Diabetes Care"},{"key":"1137_CR5","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1161\/HYPERTENSIONAHA.117.09764","volume":"70","author":"C Savoia","year":"2017","unstructured":"Savoia C, Touyz RM. Hypertension, diabetes mellitus, and excess cardiovascular risk: importance of baseline systolic blood pressure. Hypertens. 2017;70:882\u20133.","journal-title":"Hypertens"},{"key":"1137_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2337\/diacare.13.3.37","volume":"13","author":"LS Hermann","year":"1990","unstructured":"Hermann LS. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care. 1990;13:37\u201341.","journal-title":"Diabetes Care"},{"key":"1137_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.amjhyper.2003.11.006","volume":"17","author":"D Manzella","year":"2004","unstructured":"Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens. 2004;17:223\u20137.","journal-title":"Am J Hypertens"},{"key":"1137_CR8","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1111\/dom.14107","volume":"22","author":"J Kraaijenhof","year":"2020","unstructured":"Kraaijenhof J, Muskiet MHA, Tonneijck L, Ouwens DM, Kramer MHH, van Raalte DH, et al. Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: a secondary analysis of an 8-week, randomized, controlled, double-blind trial. Diabetes Obes Metab. 2020;22:1847\u201356.","journal-title":"Diabetes Obes Metab"},{"issue":"3 Pt 2","key":"1137_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/01.HYP.27.3.619","volume":"27","author":"JS Petersen","year":"1996","unstructured":"Petersen JS, DiBona GF. Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats. Hypertension. 1996;27(3 Pt 2):619\u201325.","journal-title":"Hypertension"},{"key":"1137_CR10","doi-asserted-by":"publisher","first-page":"660793","DOI":"10.3389\/fendo.2021.660793","volume":"12","author":"CCDS Franco","year":"2021","unstructured":"Franco CCDS, Previate C, Trombini AB, Miranda RA, Barella LF, Saavedra LPJ, et al. Metformin improves autonomic nervous system imbalance and metabolic dysfunction in monosodium L-glutamate-treated rats. Front Endocrinol. 2021;12:660793.","journal-title":"Front Endocrinol"},{"issue":"1","key":"1137_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12882-021-02587-5","volume":"23","author":"D Banerjee","year":"2022","unstructured":"Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, et al. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the renal association UK guideline update 2021. BMC Nephrol. 2022;23(1):9.","journal-title":"BMC Nephrol"},{"key":"1137_CR12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0895-7061(98)00049-1","volume":"11","author":"H Tomiyama","year":"1998","unstructured":"Tomiyama H, Kimura Y, Sakuma Y, Shiojima K, Yamamoto A, Saito I, et al. Effects of an ACE inhibitor and a calcium channel blocker on cardiovascular autonomic nervous system and carotid distensibility in patients with mild to moderate hypertension. Am J Hypertens. 1998;11:682\u20139.","journal-title":"Am J Hypertens"},{"key":"1137_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11906-001-0094-7","volume":"3","author":"FH Leenen","year":"2001","unstructured":"Leenen FH, Ruzicka M, Huang BS. Central sympathoinhibitory effects of calcium channel blockers. Curr Hypertens Rep. 2001;3:314\u201321.","journal-title":"Curr Hypertens Rep"},{"key":"1137_CR14","doi-asserted-by":"publisher","first-page":"6719239","DOI":"10.1155\/2017\/6719239","volume":"2017","author":"T Didangelos","year":"2017","unstructured":"Didangelos T, Tziomalos K, Margaritidis C, Kontoninas Z, Stergiou I, Tsotoulidis S, et al. Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for two years on autonomic and peripheral neuropathy in patients with diabetes mellitus. J Diabetes Res. 2017;2017:6719239.","journal-title":"J Diabetes Res"},{"key":"1137_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2169\/internalmedicine.32.691","volume":"32","author":"M Saitoh","year":"1993","unstructured":"Saitoh M, Miyakoda H, Kitamura H, Kinugawa T, Kotake H, Mashiba H. Effects of an angiotensin-converting enzyme inhibitor, alacepril, on cardiovascular and sympathetic nervous responses to mental stress in patients with essential hypertension. Intern Med. 1993;32:691\u20134.","journal-title":"Intern Med"},{"key":"1137_CR16","first-page":"182","volume":"4","author":"G Jayakrishnan","year":"2017","unstructured":"Jayakrishnan G, Pal GK, Kamalanathan S, Pal P, Sirisha A, Nanda N. Association of Prehypertension Status with cardiovascular risks in subclinical hypothyroidism. Int J Clin Exp Physiol. 2017;4:182\u20139.","journal-title":"Int J Clin Exp Physiol"},{"key":"1137_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/07435800.2016.1181648","volume":"42","author":"AN Syamsunder","year":"2017","unstructured":"Syamsunder AN, Pal P, Pal GK, Kamalanathan CS, Parija SC, Nanda N, et al. Decreased baroreflex sensitivity is linked to the atherogenic index, retrograde inflammation, and oxidative stress in subclinical hypothyroidism. Endocr Res. 2017;42:49\u201358.","journal-title":"Endocr Res"},{"key":"1137_CR18","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.metabol.2015.09.009","volume":"64","author":"J Indumathy","year":"2015","unstructured":"Indumathy J, Pal GK, Pal P, Ananthanarayanan PH, Parija SC, Balachander J, et al. Decreased baroreflex sensitivity is linked to sympathovagal imbalance, body fat mass and altered cardiometabolic profile in pre-obesity and obesity. Metabolism. 2015;64:1704\u201314.","journal-title":"Metabolism"},{"key":"1137_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/07435800.2014.920350","volume":"40","author":"S Kuppusamy","year":"2015","unstructured":"Kuppusamy S, Pal GK, Habeebullah S, Ananthanarayanan PH, Pal P. Association of sympathovagal imbalance with cardiovascular risks in patients with polycystic ovary syndrome. Endocr Res. 2015;40:37\u201343.","journal-title":"Endocr Res"},{"key":"1137_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/ajh\/hpt219","volume":"27","author":"GK Pal","year":"2014","unstructured":"Pal GK, Adithan C, Ananthanarayanan PH, Pal P, Nanda N, Durgadevi T, et al. Effects of gender on sympathovagal imbalance, prehypertension status, and cardiovascular risks in first-degree relatives of type 2 diabetics. Am J Hypertens. 2014;27:317\u201324.","journal-title":"Am J Hypertens"},{"key":"1137_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/07435800.2015.1076454","volume":"41","author":"GS Keerthi","year":"2016","unstructured":"Keerthi GS, Pal P, Pal GK, Sahoo JP, Sridhar MG, Balachander J. Attenuated baroreflex sensitivity in normotensive prediabetes and diabetes in Indian adults. Endocr Res. 2016;41:89\u201397.","journal-title":"Endocr Res"},{"key":"1137_CR22","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.amjcard.2013.07.040","volume":"112","author":"GK Pal","year":"2013","unstructured":"Pal GK, Adithan C, Ananthanarayanan PH, Pal P, Nanda N, Thiyagarajan D, et al. Association of sympathovagal imbalance with cardiovascular risks in young prehypertensives. Am J Cardiol. 2013;112:1757\u201362.","journal-title":"Am J Cardiol"},{"key":"1137_CR23","unstructured":"Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task force of the European Society of Cardiology and the north American Society of Pacing and Electrophysiology. Circulation. 1996;93:1043\u201365."},{"key":"1137_CR24","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","volume":"109","author":"S Kiechl","year":"2004","unstructured":"Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175\u201380.","journal-title":"Circulation"},{"key":"1137_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12872-020-01729-1","volume":"20","author":"MR Jasmine","year":"2020","unstructured":"Jasmine MR, Nanda N, Sahoo J, Velkumary S, Pal GK. Increased osteoprotegerin level is associated with impaired cardiovagal modulation in type-2 diabetic patients treated with oral antidiabetic drugs. BMC Cardiovasc Disord. 2020;20:453.","journal-title":"BMC Cardiovasc Disord"},{"key":"1137_CR26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2337\/diacare.28.3.668","volume":"28","author":"EB Schroeder","year":"2005","unstructured":"Schroeder EB, Chambless LE, Liao D, Prineas RJ, Evans GW, Rosamond WD, et al. Diabetes, glucose, insulin, and heart rate variability: the atherosclerosis risk in communities (ARIC) study. Diabetes Care. 2005;28:668\u201374.","journal-title":"Diabetes Care"},{"key":"1137_CR27","first-page":"1995","volume":"10","author":"SM Williams","year":"2019","unstructured":"Williams SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac autonomic neuropathy in obesity, the metabolic syndrome and prediabetes: a narrative review. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2019;10:1995\u20132021.","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"46","key":"1137_CR28","first-page":"162","volume":"2005","author":"J Ruiz","year":"1979","unstructured":"Ruiz J, Monbaron D, Parati G, Perret S, Haesler E, Danzeisen C, et al. Diabetic neuropathy is a more important determinant of baroreflex sensitivity than carotid elasticity in type 2 diabetes. Hypertens Dallas Tex. 1979;2005(46):162\u20137.","journal-title":"Hypertens Dallas Tex"},{"key":"1137_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.7326\/M17-0939","volume":"168","author":"A Quaseem","year":"2018","unstructured":"Quaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for non pregnant adults with type 2 diabetes mellitus: a guidance statemrnt update from the American Coolege of physicians. Ann Inter Med. 2018;168:569\u201376.","journal-title":"Ann Inter Med"},{"key":"1137_CR30","first-page":"123","volume":"27","author":"H Majid","year":"2017","unstructured":"Majid H, Masood Q, Khan AH. Homeostatic model assessment for insulin resistance (HOMA-IR): a better marker for evaluating insulin resistance than fasting insulin in women with polycystic ovarian syndrome. J Coll Physicians Surg-Pak JCPSP. 2017;27:123\u20136.","journal-title":"J Coll Physicians Surg-Pak JCPSP"},{"key":"1137_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1161\/01.CIR.78.4.816","volume":"78","author":"MT La Rovere","year":"1988","unstructured":"La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. Circulation. 1988;78:816\u201324.","journal-title":"Circulation"},{"key":"1137_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1542-474X.2008.00219.x","volume":"13","author":"MT La Rovere","year":"2008","unstructured":"La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: measurement and clinical implications. Ann Noninvasive Electrocardiol Off J Int Soc Holter Noninvasive Electrocardiol Inc. 2008;13:191\u2013207.","journal-title":"Ann Noninvasive Electrocardiol Off J Int Soc Holter Noninvasive Electrocardiol Inc"},{"key":"1137_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34:575\u201384.","journal-title":"Can J Cardiol"},{"key":"1137_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12933-018-0683-2","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Iuchi H, Minato S, Suzuki H, Kayama Y, et al. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2018;17:36.","journal-title":"Cardiovasc Diabetol"},{"key":"1137_CR35","doi-asserted-by":"crossref","unstructured":"Lampropoulou I-T, Stangou M, Papagianni A, Didangelos T, Iliadis F, Efstratiadis G. TNF-\u03b1 and microalbuminuria in patients with type 2 diabetes mellitus. J Diabetes Res. 2014;2014:394206.","DOI":"10.1155\/2014\/394206"},{"key":"1137_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.diabres.2011.07.037","volume":"94","author":"M Mishra","year":"2011","unstructured":"Mishra M, Kumar H, Bajpai S, Singh RK, Tripathi K. Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. Diabetes Res Clin Pract. 2011;94:255\u201361.","journal-title":"Diabetes Res Clin Pract"},{"key":"1137_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ndt\/gfl019","volume":"21","author":"P Pauletto","year":"2006","unstructured":"Pauletto P, Rattazzi M. Inflammation and hypertension: the search for a link. Nephrol Dial Transplant. 2006;21:850\u20133.","journal-title":"Nephrol Dial Transplant"},{"key":"1137_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/sj.jhh.1001785","volume":"19","author":"LE Bautista","year":"2005","unstructured":"Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6 and TNF-\u03b1) and essential hypertension. J Hum Hypertens. 2005;19:149\u201354.","journal-title":"J Hum Hypertens"},{"key":"1137_CR39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1186\/2193-1801-2-658","volume":"2","author":"M Bjerre","year":"2013","unstructured":"Bjerre M. Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. SpringerPlus. 2013;2:658.","journal-title":"SpringerPlus"},{"key":"1137_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1055\/s-2005-861371","volume":"37","author":"LM Rasmussen","year":"2005","unstructured":"Rasmussen LM, Ledet T. Osteoprotegerin and diabetic macroangiopathy. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2005;37:90\u20134.","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"1137_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/eje.0.1490039","volume":"149","author":"ST Knudsen","year":"2003","unstructured":"Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003;149:39\u201342.","journal-title":"Eur J Endocrinol"},{"key":"1137_CR42","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.metabol.2009.09.019","volume":"59","author":"I Nabipour","year":"2010","unstructured":"Nabipour I, Kalantarhormozi M, Larijani B, Assadi M, Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism. 2010;59:742\u20137.","journal-title":"Metabolism"},{"key":"1137_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/JIR.S148911","volume":"11","author":"C Pouvreau","year":"2018","unstructured":"Pouvreau C, Dayre A, Butkowski EG, de Jong B, Jelinek HF. Inflammation and oxidative stress markers in diabetes and hypertension. J Inflamm Res. 2018;11:61\u20138.","journal-title":"J Inflamm Res"},{"key":"1137_CR44","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1161\/01.HYP.26.6.869","volume":"26","author":"JR Sowers","year":"1995","unstructured":"Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertens. 1995;26:869\u201379.","journal-title":"Hypertens"},{"key":"1137_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s11883-012-0227-2","volume":"14","author":"BMY Cheung","year":"2012","unstructured":"Cheung BMY, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. 2012;14:160\u20136.","journal-title":"Curr Atheroscler Rep"},{"key":"1137_CR46","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.2337\/dcS15-3015","volume":"39","author":"RM Pollack","year":"2016","unstructured":"Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care. 2016;39:S244\u201352.","journal-title":"Diabetes Care"},{"key":"1137_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/FJC.0b013e318135446c","volume":"50","author":"S Del Colle","year":"2007","unstructured":"Del Colle S, Morello F, Rabbia F, Milan A, Naso D, Puglisi E, et al. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol. 2007;50:487\u201396.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1137_CR48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ajh\/hpw012","volume":"29","author":"G Grassi","year":"2016","unstructured":"Grassi G. Sympathomodulatory effects of antihypertensive drug treatment. Am J Hypertens. 2016;29:665\u201375.","journal-title":"Am J Hypertens"},{"key":"1137_CR49","first-page":"322","volume-title":"Comprehensive textbook of medical physiology","author":"GK Pal","year":"2019","unstructured":"Pal GK, Pal P, Nanda N. Heart rate variability. In:  Comprehensive textbook of medical physiology. 2nd ed. New Delhi: Jaypee Publications; 2019. p. 322\u20137.","edition":"2"},{"key":"1137_CR50","doi-asserted-by":"publisher","first-page":"50S","DOI":"10.1016\/S0895-7061(98)00280-5","volume":"12","author":"WB White","year":"1999","unstructured":"White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens. 1999;12:50S\u20135S.","journal-title":"Am J Hypertens"},{"key":"1137_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000322822","volume":"1","author":"JR Sowers","year":"2011","unstructured":"Sowers JR, Whaley-Connell A, Hayden MR. The role of overweight and obesity in the Cardiorenal syndrome. Cardiorenal Med. 2011;1:5\u201312.","journal-title":"Cardiorenal Med"},{"key":"1137_CR52","first-page":"2727","volume":"15","author":"F Massi\u00e9ra","year":"2001","unstructured":"Massi\u00e9ra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J Off Publ Fed Am Soc Exp Biol. 2001;15:2727\u20139.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"1137_CR53","doi-asserted-by":"publisher","first-page":"R943","DOI":"10.1152\/ajpregu.00265.2004","volume":"287","author":"CM Boustany","year":"2004","unstructured":"Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol. 2004;287:R943\u20139.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1137_CR54","first-page":"269","volume-title":"Textbook of practical physiology","author":"GK Pal","year":"2020","unstructured":"Pal GK, Pal P. Blood pressure variability and baroreflex sensitivity. In:  Textbook of practical physiology. 5th ed. Hyderabad: Universities Press; 2020. p. 269\u201374.","edition":"5"},{"key":"1137_CR55","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.clnu.2017.05.012","volume":"37","author":"Y Nurdiantami","year":"2018","unstructured":"Nurdiantami Y, Watanabe K, Tanaka E, Pradono J, Anme T. Association of general and central obesity with hypertension. Clin Nutr Edinb Scotl. 2018;37:1259\u201363.","journal-title":"Clin Nutr Edinb Scotl"},{"key":"1137_CR56","first-page":"73","volume":"111","author":"PF Martinez","year":"2018","unstructured":"Martinez PF, Okoshi MP. Heart rate variability in coexisting diabetes and hypertension. Arq Bras Cardiol. 2018;111:73\u20134.","journal-title":"Arq Bras Cardiol"},{"key":"1137_CR57","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/ki.1997.207","volume":"51","author":"K Hayashi","year":"1997","unstructured":"Hayashi K, Fujiwara K, Oka K, Nagahama T, Matsuda H, Saruta T. Effects of insulin on rat renal microvessels: studies in the isolated perfused hydronephrotic kidney. Kidney Int. 1997;51:1507\u201313.","journal-title":"Kidney Int"},{"key":"1137_CR58","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1097\/00004872-199917090-00001","volume":"17","author":"LA Sechi","year":"1999","unstructured":"Sechi LA. Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J Hypertens. 1999;17:1229\u201337.","journal-title":"J Hypertens"},{"key":"1137_CR59","doi-asserted-by":"crossref","unstructured":"Horita S, Seki G, Yamada H, Suzuki M, Koike K, Fujita T. Insulin resistance, obesity, hypertension, and renal sodium transport. Int. J Hypertens.\u00a02011;2011:391762.","DOI":"10.4061\/2011\/391762"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01137-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01137-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01137-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T15:13:05Z","timestamp":1662736385000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01137-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01137-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"2 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the JIPMER Institute Ethics Committee [JIP\/IEC\/2018\/305]. All methods in the study were performed in accordance with the Helsinki declarations. All data of the study were anonymised and coded before its use. Written informed consent to use the biological sample and case history was obtained from each participant after explaining the purpose, and procedure of the study in their vernacular language.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}